Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting, Discover our latest financial performance announcement and search for historical quarterly results materials, Explore the latest news, different ways to stay in touch and available useful resources, Keep up to date with our news and recent announcements. The transaction, which was announced on 3 December 2018, significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. Other tests, such as MyChoice and FoundationOne have been used in clinical trials of ovarian cancer to identify patients whose tumors have HRD and are sensitive to PARP inhibitors. Discontinue Zejula if MDS/AML is confirmed. © 2001-2020 GlaxoSmithKline plc. GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). GSK also believes PARP inhibitors offer significant opportunities for use in the treatment of multiple cancer types. Guidance and Group Outlooks are given on the bases set out on pages 37 and 38 of GSK’s Q3 2018 results, including definitions of CER growth and Adjusted results. No representation or warranty (express or implied) of any nature is given, nor is any responsibility or liability of any kind accepted, with respect to the truthfulness, completeness or accuracy of any information, projection, statement or omission in this release. Structure and Terms of the Transaction Under the terms of the merger agreement between GSK and TESARO, unanimously approved by TESARO’s Board of Directors, an indirect subsidiary of GSK will commence a tender offer within the next 10 business days to acquire all of the issued and outstanding shares of TESARO common stock for a price of $75 per share in cash upon completion of the offer. PARP inhibitors have shown activity as a monotherapy against tumours with existing DNA repair defects, such as BRCA1 and BRCA2, and as a combination therapy when administered together with anti- cancer agents that induce DNA damage or activate the immune system. We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare. I am excited to be partnering with our new colleagues at GSK as together we advance innovative scientific and drug development strategies that ultimately enable us to provide more time for more patients.”. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017. Hematologic adverse reactions (thrombocytopenia, anemia and neutropenia), as well as cardiovascular effects (hypertension and hypertensive crisis) have been reported in patients treated with Zejula. We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare. Accordingly, AAC has accepted for payment and has paid the depositary for all validly tendered Shares. PARP inhibitors are transforming the treatment of ovarian cancer, notably demonstrating marked clinical benefit in patients with and without germline mutations in a BRCA gene (gBRCA). The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. Mutations in this gene can prevent DNA repair. PARP proteins play key roles in single strand break repair through the base excision repair pathway. Zejula is currently approved in the US and Europe as a treatment for adult patients with recurrent ovarian cancer who are in response to platinum-based chemotherapy, regardless of BRCA mutation or biomarker status. Images can be downloaded in low and high resolution. At the time the tender offer is commenced, GSK and Adriatic Acquisition Corporation will file, or will cause to be filed, a Schedule TO Tender Offer Statement with the SEC, and, thereafter, TESARO will file a Schedule 14D-9 Solicitation/Recommendation Statement with the SEC, in each case with respect to the tender offer. Zejula is currently approved in the US and Europe as a treatment for adult patients with recurrent ovarian cancer who are in response to platinum-based chemotherapy, regardless of BRCA mutation or biomarker status. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. Forward-looking statements include, without limitation, statements regarding the business combination, similar transactions, prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for TESARO’s business; the commercial success of TESARO’s products; the anticipated timing of clinical data; the possibility of unfavorable results from clinical trials; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; and the accuracy of any assumptions underlying any of the foregoing. Mutations or aberrations in BRCA or other genes that prevent DNA repair result in a state of homologous recombination deficiency, or “HRD”. 3888792.Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. This communication is for informational purposes only and is neither a recommendation, an offer to purchase nor a solicitation of an offer to sell securities. GSK’s pipeline is focused on immuno-oncology, cell therapy, and epigenetics. In preclinical studies, Zejula concentrates in the tumour relative to plasma, delivering greater than 90% durable inhibition of PARP 1/2 and a persistent antitumour effect. You are currently visiting our global website. The following pages provide information about our R&D work in oncology. On December 14, 2018, GSK, GlaxoSmithKline LLC and AAC filed with the SEC a tender offer statement on Schedule TO regarding the tender offer described in this communication. Vorbörslich, nach Bekanntwerden der Tesaro-Übernahme durch GSK, legt die Aktie satte 30 Prozent zu. Citi is serving as TESARO’s lead financial advisor, with Centerview Partners also providing financial advice. 3888792. 3888792.Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. GSK continues to expect to deliver on its previously published Group Outlooks to 2020, but following the acquisition of TESARO now expects Adjusted EPS growth at CER for the period 2016-2020 to be at the bottom end of the mid to high single digit percentage CAGR range. In addition to the Schedule 14D-9 Solicitation/Recommendation Statement and Schedule TO Offer Statement (once each becomes available), TESARO and GSK file or furnish, as applicable, annual, quarterly and current reports and other information with the SEC. TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer. The transaction is expected to complete in the first quarter of 2019, subject to satisfaction of customary closing conditions, including the tender by TESARO stockholders of at least one share more than 50% of the issued and outstanding shares of TESARO and required regulatory approvals, including clearance by the US Federal Trade Commission. PARP inhibitors are transforming the treatment of ovarian cancer, notably demonstrating marked clinical benefit in patients with and without germline mutations in a BRCA gene (gBRCA). We want to help change this, using our scientific expertise, our partnerships and our global reach. Zejula’s revenues in its current approved indication as second-line maintenance treatment for ovarian cancer were $166 million for the 9 months ended 30 September 2018. Whyte, Company Secretary. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. The tender offer statement and other documents filed by GSK and TESARO with the SEC are available for free at the SEC’s website at www.sec.gov. Zejula can cause fetal harm and females of reproductive potential should use effective contraception. Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines. We are also very excited that through this transaction, we will have the opportunity to work with an outstanding Boston-based oncology group with deep clinical development expertise and together we will explore Zejula’s efficacy beyond ovarian cancer into multiple tumour types to help many more patients.”Lonnie Moulder, Chief Executive Officer, TESARO, said: “This transaction marks the beginning of a new global partnership that will accelerate our oncology business and allow our mission of delivering transformative products to individuals living with cancer to endure. GSK also believes PARP inhibitors offer significant opportunities for use in the treatment of multiple cancer types. We are a global company delivering billions of healthcare products a year. Visit our Careers section and choose your path. For further information please visit www.gsk.com/about-us. © 2001-2020 GlaxoSmithKline plc. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of TESARO’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effects of the transaction (or the announcement thereof) on relationships with associates, customers, other business partners or governmental entities; transaction costs; the risk that the merger will divert management’s attention from TESARO’s ongoing business operations; changes in TESARO’s businesses during the period between now and the closing; risks associated with litigation; and other risks and uncertainties detailed from time to time in documents filed with the Securities and Exchange Commission by TESARO, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by TESARO. 3888792. We look forward to working with TESARO’s talented team to bring valuable new medicines to patients.”, Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Our strong belief is that PARP inhibitors are important medicines that have been under appreciated in terms of the impact they can have on cancer patients. GSK completed the acquisition of TESARO today through a merger under Section 251(h) of the General Corporation Law of the State of Delaware (the “DGCL”). Our purpose is to help people to do more, feel better, live longer. Meet some of our employees from various roles, and find out what they really think about working life with us. This combination will support our aim to deliver long-term sustainable growth and is consistent with our capital allocation priorities. Find out about our focus on oncology R&D 2. Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting, Discover our latest financial performance announcement and search for historical quarterly results materials, Explore the latest news, different ways to stay in touch and available useful resources, Keep up to date with our news and recent announcements. Legal advice is being provided by Ropes & Gray LLP, and Hogan Lovells.

Pfizer Uk Management Team, Des Mini Series Release Date, Bentley Apartments For Rent, Texas Rangers Logo 2020, Defuniak Herald Contact, Mark Knopfler - Get Lucky Full Album, Sample Ballot Memphis Tn 2020, Easton Pa Police Blotter, Virgin Islands Dor, City Of Austin Zoning Guide, Non Homestead Taxes Michigan, Volusia County Calendar Of Events, Rbh Vacancies, Bexar County Justice Of The Peace Precinct 1, Car Seat Adjustment Mechanism, You Slayed It Girl, Giovanna Nickname, Articolo Domi Wall Sconce, Princess Theatre Virtual Seating, You Got To Me Neil Diamond Wiki, 10am Pdt To Edt, Benton Construction Usvi, Ethan Berkowitz Email, Pretty Woman Musical Songs, Distance Vryburg To Kuruman, The Stranglers - Always The Sun Lyrics, Folklore Youtube, 6033 S Sossaman Rd, Mesa, Az 85212, Prince Of Wales Theatre Seat View, Majestic Cinemas Showtimes, Elizabethan Fashion, Theatre Victoria, Texas, Blagoy Ivanov Sherdog, Challenge Platform Curtin, Rollins Edriving, Stampede Park, Spring Water Benefits, Best Jockeys In The World 2020, Hardwell Conquerors, Serafines Definicion, Fire Names, How To Get Amazon Prime Student Without Being A Student Reddit, St Cloud Times Address, Eit New Zealand Course Fees, Used Jewelry For Sale By Owner, Why Is The Colosseum Broken, Al Green Let's Stay Together (vinyl), Phillip 2 Macedon, Phoenix Theatre Company, St Joseph In Elgin, Il, What Was Christopher Columbus Looking For, West Middlesex Hospital Blood Test, Pluriportail Csb, Winx Club Season 7 Episode 25 Dailymotion, Attack On Titan All Titans, Cuna Cpd Online, Vehicle Maintenance Book Pdf, Supraclavicular Lymph Nodes Swollen Right Side Causes, Brown Eyed Girl Chords Ukulele, What Is The Average Rainfall In The Amazon Rainforest, Gillian Lynne Husband, Edna Testing, Https Www Amazon Com Myac, Maradona Sevilla, Kempton Park Steam Engines Video, London North West University Healthcare Nhs Trust Address, Ashia Name Pronunciation, Book Of Mormon Tickets Discount,